Newest joint application of two enabling medical technologies exhibits
benefits of intraoperative MRI for direct visualization when navigating
to treat brain tumors and neurological disorders
MINNEAPOLIS, MN and IRVINE, CA, Aug. 20, 2013 /PRNewswire/ - IMRIS Inc.
(NASDAQ: IMRS; TSX: IM) ("IMRIS") and MRI Interventions, Inc. (OTCQB:
MRIC) today announced that a surgical team at Brigham and Women's
Hospital (BWH) in Boston, MA, has performed the first laser ablation
procedure to combine the use of MRI Interventions' ClearPoint® Neuro Intervention System as the navigation platform with
intraoperative MRI (iMRI) in an IMRIS VISIUS® Surgical Theatre. The combination of these two enabling technologies
provided continuous visualization and guidance throughout a
neurosurgical intervention to treat a right frontal brain tumor.
"The combination of the two technologies made for a smooth and
successful operation," said Dr. Alexandra Golby, BWH neurosurgeon and
associate professor of surgery at Harvard Medical School. "We had
access to excellent real-time MR images within a hi-tech surgical suite
and were able to use those images to guide and deliver the needed
therapy to specific targets in the brain with a high degree of
The ClearPoint navigation platform enables minimally-invasive
neurosurgery under continuous MR guidance, and offers surgeons a direct
view of the inside of a patient's brain during a procedure. The VISIUS
Surgical Theatre allows use of intraoperative MRI right inside the
operating room and over the OR table.
Using the ClearPoint system with VISIUS iMRI, Golby was able to see and
select the lesion of the tumor in the brain, establish a safe
trajectory, and visualize the laser catheter on MR images as it was
inserted to the desired location. She was then able to utilize
real-time MR thermometry to monitor progress as the laser catheter
heated the target area to the desired temperature for therapeutic
destruction of the malignant tissue, preserving surrounding healthy
tissue in the process. MRI is the only imaging technology that will
safely allow this continuous soft tissue visualization during surgery.
Finally, Golby was able to confirm results of the procedure using the
MRI before the patient was removed from the operating table.
Installed at Brigham and Women's Hospital in 2011, the IMRIS VISIUS
Surgical Theatre features a high-field iMRI that travels on-demand
between operating and angiography rooms on ceiling rails. The
multi-disciplinary suite provides truly intraoperative imaging as it
does not require the patient to be moved from the OR table for scanning
during surgery, so optimal positioning for neurosurgery is not
compromised and typical clinical workflow is not impacted.
In addition to focal laser ablation, the ClearPoint system has been used
within a VISIUS Surgical Theatre to facilitate direct drug delivery in
the brain and deep brain stimulator electrode placement. Brain biopsy
is another potential joint application of these technologies.
About MRI Interventions, Inc.
Founded in 1998, MRI Interventions is creating innovative platforms for
performing the next generation of minimally invasive surgical
procedures in the brain and heart. Utilizing a hospital's existing MRI
suite, the company's FDA-cleared and CE-marked ClearPoint® system is designed to enable a range of minimally invasive procedures
in the brain. MRI Interventions has a co-development and
co-distribution agreement with Brainlab, a leader in software-driven
medical technology, relating to the ClearPoint system. In partnership
with Siemens Healthcare, MRI Interventions is developing the ClearTrace® system to enable MRI-guided catheter ablations to treat cardiac
arrhythmias, including atrial fibrillation. Building on the imaging
power of MRI, the company's interventional platforms strive to improve
patient care while reducing procedure costs and times. MRI
Interventions is also working with Boston Scientific Corporation to
incorporate its MRI-safety technologies into Boston Scientific's
implantable leads for cardiac and neurological applications. For more
information, please visit www.mriinterventions.com.
About IMRIS, Inc.
IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image
guided therapy solutions through its VISIUS Surgical Theatre - a
revolutionary, multifunctional surgical environment that provides
unmatched intraoperative vision to clinicians to assist in decision
making and enhance precision in treatment. The multi-room suites
incorporate diagnostic quality high-field MR, CT and angio modalities
accessed effortlessly in the operating room setting. VISIUS Surgical
Theatres serve the neurosurgical, spinal, cardiovascular and
cerebrovascular markets and have been selected by 54 leading medical
institutions around the world.
Certain matters in this press release may constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements often can be identified by words such as
"anticipates," "believes," "could," "estimates," "expects," "intends,"
"may," "plans," "potential," "predicts," "projects," "should," "will,"
"would," or the negative of these words or other words of similar
meaning. Forward-looking statements by their nature address matters
that, to different degrees, are uncertain and involve risk.
Uncertainties and risks may cause MRI Interventions' actual results and
the timing of events to differ materially from those expressed in or
implied by MRI Interventions' forward-looking statements. Particular
uncertainties and risks include, among others: demand and market
acceptance of our products; our ability to successfully expand our
sales and marketing capabilities; our ability to successfully complete
the development of, and to obtain regulatory clearance or approval for,
future products, including our current product candidates; availability
of third party reimbursement; the sufficiency of our cash resources to
maintain planned commercialization efforts and research and development
programs; future actions of the FDA or any other regulatory body that
could impact product development, manufacturing or sale; our ability to
protect and enforce our intellectual property rights; our dependence on
collaboration partners; the impact of competitive products and pricing;
and the impact of the commercial and credit environment on us and our
customers and suppliers. More detailed information on these and
additional factors that could affect MRI Interventions' actual results
are described in MRI Interventions' filings with the Securities and
Exchange Commission, including, without limitation, MRI Interventions'
Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission on May 10, 2013. Except as required by law, MRI
Interventions undertakes no obligation to publicly update or revise any
forward-looking statements contained in this press release to reflect
any change in MRI Interventions' expectations or any change in events,
conditions or circumstances on which any such statements are based.
SOURCE IMRIS Inc.
Image with caption: "IMRIS iMRI (CNW Group/IMRIS Inc.)". Image available at: http://photos.newswire.ca/images/download/20130820_C6910_PHOTO_EN_29980.jpg